反应性硬化对MR-HIFU治疗骨样骨瘤疗效的影响
这项前瞻性研究纳入18例四肢症状性骨样骨瘤患者,评估临床和手术因素(尤其是反应性硬化厚度)对MR-HIFU临床结局的影响。结果显示FACT-BP评分从基线29.7显著改善至6个月随访5.5和12个月随访3.4(均p<0.01),FACT-BP评分与瘤巢周围反应性硬化厚度强相关(6个月随访r=0.62,p=0.006),预测良好临床结局的最佳截断值为0.6 cm。作者结论认为MR-HIFU是治疗儿童和成人四肢症状性骨样骨瘤的有效方法,反应性硬化厚度是影响患者结局的相关因素。
要点
- MR-HIFU治疗后FACT-BP评分从基线29.7显著改善至6个月随访5.5、12个月随访3.4(均p<0.01)。
- FACT-BP评分与瘤巢周围反应性硬化厚度强相关(6个月随访r=0.62,p=0.006)。
- 预测良好临床结局的反应性硬化厚度最佳截断值为0.6 cm。
核心结论
- MR-HIFU是治疗儿童和成人四肢症状性骨样骨瘤的有效方法,瘤巢周围反应性硬化厚度是影响患者结局的相关因素,强调其在MR-HIFU评估和规划中的重要性。
研究设计与样本
- 正在进行的MR-HIFU治疗四肢症状性骨样骨瘤的前瞻性研究(德国临床试验注册号DRKS00015448),纳入18例连续患者(中位年龄19.5岁)。
- 采用FACT-BP评分在干预后1周、2周、1个月、6个月和12个月随访评估症状和生活质量参数。
- 干预前及干预后6个月和12个月行MRI检查,评估手术和影像参数,特别关注瘤巢周围反应性硬化厚度。
关键影像表现/征象
- 评估参数包括手术和影像参数,特别关注瘤巢周围反应性硬化厚度。
诊断标准与关键数值
- FACT-BP评分与瘤巢周围反应性硬化厚度强相关(6个月随访r=0.62,p=0.006),预测良好临床结局的最佳截断值为0.6 cm。
- FACT-BP平均评分:基线29.7,6个月随访5.5,12个月随访3.4,基线与所有随访间均显著改善(均p<0.01)。
临床应用与阅片要点
- 作者强调瘤巢周围反应性硬化厚度是影响MR-HIFU治疗四肢症状性骨样骨瘤患者结局的相关因素,在MR-HIFU评估和规划中具有重要性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the influence of clinical and procedural factors, particularly the thickness of reactive sclerosis, on clinical outcome of MR-guided high-intensity focused ultrasound (MR-HIFU) for the treatment of symptomatic osteoid osteomas (OO) of the extremities.
MATERIALS AND METHODS: 18 consecutive patients (median age 19.5y) with symptomatic OO of the extremities eligible for MR-HIFU were enrolled in this ongoing prospective study (German Clinical Trials Register; nr. DRKS00015448). The Functional Assessment of Cancer Therapy - Bone Pain (FACT-BP) score was used for evaluation of symptoms and quality of life parameters at 1-week, 2-week, 1-month, 6-month and 12-month follow-up (FU) after intervention. MRI was performed prior as well as, 6 and 12 months after intervention. Assessment included procedural and imaging parameters, with a specific focus on the thickness of the reactive sclerosis surrounding the nidus.
RESULTS: Symptoms and quality of life parameters significantly improved between baseline and all FUs on the FACT-BP (mean score at baseline: 29.7; at 6-month-FU: 5.5; at 12-month-FU: 3.4, all p < 0.01). A strong correlation was found between scores of FACT-BP and the thickness of reactive sclerosis surrounding the nidus (r = 0.62 at 6-month-FU; p = 0.006) with an optimal cutoff of 0.6 cm identified for predicting a good clinical outcome.
CONCLUSION: MR-HIFU is an effective method for the treatment of symptomatic osteoid osteomas of the extremities in pediatric and adult patients, with the thickness of reactive sclerosis surrounding the nidus being a relevant factor influencing patient outcomes and emphasizing its importance in MR-HIFU assessment and planning.
引用
- Erber B, Geßl A, Reidler P, et al. Impact of reactive sclerosis on outcome of MR-HIFU for osteoid osteomas. Eur J Radiol. 2024. PMID: 39753004. doi:10.1016/j.ejrad.2024.111902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。